Long-term impact of fecal transplantation in healthy volunteers
Abstract Background Fecal microbiota transplantation (FMT) has been recently approved by FDA for the treatment of refractory recurrent clostridial colitis (rCDI). Success of FTM in treatment of rCDI led to a number of studies investigating the effectiveness of its application in the other gastrointe...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-12-01
|
Series: | BMC Microbiology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12866-019-1689-y |
id |
doaj-78f30b949a854bfb94166405a8166d93 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Oleg V. Goloshchapov Evgenii I. Olekhnovich Sergey V. Sidorenko Ivan S. Moiseev Maxim A. Kucher Dmitry E. Fedorov Alexander V. Pavlenko Alexander I. Manolov Vladimir V. Gostev Vladimir A. Veselovsky Ksenia M. Klimina Elena S. Kostryukova Evgeny A. Bakin Alexander N. Shvetcov Elvira D. Gumbatova Ruslana V. Klementeva Alexander A. Shcherbakov Margarita V. Gorchakova Juan José Egozcue Vera Pawlowsky-Glahn Maria A. Suvorova Alexey B. Chukhlovin Vadim M. Govorun Elena N. Ilina Boris V. Afanasyev |
spellingShingle |
Oleg V. Goloshchapov Evgenii I. Olekhnovich Sergey V. Sidorenko Ivan S. Moiseev Maxim A. Kucher Dmitry E. Fedorov Alexander V. Pavlenko Alexander I. Manolov Vladimir V. Gostev Vladimir A. Veselovsky Ksenia M. Klimina Elena S. Kostryukova Evgeny A. Bakin Alexander N. Shvetcov Elvira D. Gumbatova Ruslana V. Klementeva Alexander A. Shcherbakov Margarita V. Gorchakova Juan José Egozcue Vera Pawlowsky-Glahn Maria A. Suvorova Alexey B. Chukhlovin Vadim M. Govorun Elena N. Ilina Boris V. Afanasyev Long-term impact of fecal transplantation in healthy volunteers BMC Microbiology Fecal microbiota transplantation Healthy volunteers Metagenomics 16S rRNA gene sequencing Shotgun sequencing Metagenome-assembled genome |
author_facet |
Oleg V. Goloshchapov Evgenii I. Olekhnovich Sergey V. Sidorenko Ivan S. Moiseev Maxim A. Kucher Dmitry E. Fedorov Alexander V. Pavlenko Alexander I. Manolov Vladimir V. Gostev Vladimir A. Veselovsky Ksenia M. Klimina Elena S. Kostryukova Evgeny A. Bakin Alexander N. Shvetcov Elvira D. Gumbatova Ruslana V. Klementeva Alexander A. Shcherbakov Margarita V. Gorchakova Juan José Egozcue Vera Pawlowsky-Glahn Maria A. Suvorova Alexey B. Chukhlovin Vadim M. Govorun Elena N. Ilina Boris V. Afanasyev |
author_sort |
Oleg V. Goloshchapov |
title |
Long-term impact of fecal transplantation in healthy volunteers |
title_short |
Long-term impact of fecal transplantation in healthy volunteers |
title_full |
Long-term impact of fecal transplantation in healthy volunteers |
title_fullStr |
Long-term impact of fecal transplantation in healthy volunteers |
title_full_unstemmed |
Long-term impact of fecal transplantation in healthy volunteers |
title_sort |
long-term impact of fecal transplantation in healthy volunteers |
publisher |
BMC |
series |
BMC Microbiology |
issn |
1471-2180 |
publishDate |
2019-12-01 |
description |
Abstract Background Fecal microbiota transplantation (FMT) has been recently approved by FDA for the treatment of refractory recurrent clostridial colitis (rCDI). Success of FTM in treatment of rCDI led to a number of studies investigating the effectiveness of its application in the other gastrointestinal diseases. However, in the majority of studies the effects of FMT were evaluated on the patients with initially altered microbiota. The aim of our study was to estimate effects of FMT on the gut microbiota composition in healthy volunteers and to monitor its long-term outcomes. Results We have performed a combined analysis of three healthy volunteers before and after capsule FMT by evaluating their general condition, adverse clinical effects, changes of basic laboratory parameters, and several immune markers. Intestinal microbiota samples were evaluated by 16S rRNA gene and shotgun sequencing. The data analysis demonstrated profound shift towards the donor microbiota taxonomic composition in all volunteers. Following FMT, all the volunteers exhibited gut colonization with donor gut bacteria and persistence of this effect for almost ∼1 year of observation. Transient changes of immune parameters were consistent with suppression of T-cell cytotoxicity. FMT was well tolerated with mild gastrointestinal adverse events, however, one volunteer developed a systemic inflammatory response syndrome. Conclusions The FMT leads to significant long-term changes of the gut microbiota in healthy volunteers with the shift towards donor microbiota composition and represents a relatively safe procedure to the recipients without long-term adverse events. |
topic |
Fecal microbiota transplantation Healthy volunteers Metagenomics 16S rRNA gene sequencing Shotgun sequencing Metagenome-assembled genome |
url |
https://doi.org/10.1186/s12866-019-1689-y |
work_keys_str_mv |
AT olegvgoloshchapov longtermimpactoffecaltransplantationinhealthyvolunteers AT evgeniiiolekhnovich longtermimpactoffecaltransplantationinhealthyvolunteers AT sergeyvsidorenko longtermimpactoffecaltransplantationinhealthyvolunteers AT ivansmoiseev longtermimpactoffecaltransplantationinhealthyvolunteers AT maximakucher longtermimpactoffecaltransplantationinhealthyvolunteers AT dmitryefedorov longtermimpactoffecaltransplantationinhealthyvolunteers AT alexandervpavlenko longtermimpactoffecaltransplantationinhealthyvolunteers AT alexanderimanolov longtermimpactoffecaltransplantationinhealthyvolunteers AT vladimirvgostev longtermimpactoffecaltransplantationinhealthyvolunteers AT vladimiraveselovsky longtermimpactoffecaltransplantationinhealthyvolunteers AT kseniamklimina longtermimpactoffecaltransplantationinhealthyvolunteers AT elenaskostryukova longtermimpactoffecaltransplantationinhealthyvolunteers AT evgenyabakin longtermimpactoffecaltransplantationinhealthyvolunteers AT alexandernshvetcov longtermimpactoffecaltransplantationinhealthyvolunteers AT elviradgumbatova longtermimpactoffecaltransplantationinhealthyvolunteers AT ruslanavklementeva longtermimpactoffecaltransplantationinhealthyvolunteers AT alexanderashcherbakov longtermimpactoffecaltransplantationinhealthyvolunteers AT margaritavgorchakova longtermimpactoffecaltransplantationinhealthyvolunteers AT juanjoseegozcue longtermimpactoffecaltransplantationinhealthyvolunteers AT verapawlowskyglahn longtermimpactoffecaltransplantationinhealthyvolunteers AT mariaasuvorova longtermimpactoffecaltransplantationinhealthyvolunteers AT alexeybchukhlovin longtermimpactoffecaltransplantationinhealthyvolunteers AT vadimmgovorun longtermimpactoffecaltransplantationinhealthyvolunteers AT elenanilina longtermimpactoffecaltransplantationinhealthyvolunteers AT borisvafanasyev longtermimpactoffecaltransplantationinhealthyvolunteers |
_version_ |
1724350716100739072 |
spelling |
doaj-78f30b949a854bfb94166405a8166d932021-01-03T12:09:07ZengBMCBMC Microbiology1471-21802019-12-0119111310.1186/s12866-019-1689-yLong-term impact of fecal transplantation in healthy volunteersOleg V. Goloshchapov0Evgenii I. Olekhnovich1Sergey V. Sidorenko2Ivan S. Moiseev3Maxim A. Kucher4Dmitry E. Fedorov5Alexander V. Pavlenko6Alexander I. Manolov7Vladimir V. Gostev8Vladimir A. Veselovsky9Ksenia M. Klimina10Elena S. Kostryukova11Evgeny A. Bakin12Alexander N. Shvetcov13Elvira D. Gumbatova14Ruslana V. Klementeva15Alexander A. Shcherbakov16Margarita V. Gorchakova17Juan José Egozcue18Vera Pawlowsky-Glahn19Maria A. Suvorova20Alexey B. Chukhlovin21Vadim M. Govorun22Elena N. Ilina23Boris V. Afanasyev24R.M.Gorbacheva Memorial Institute of Oncology, Hematology and Transplantation, Pavlov First Saint Petersburg State Medical UniversityFederal Research and Clinical Centre of Physical and Chemical Medicine of Federal Medical and Biological Agency of RussiaPediatric Research and Clinical Center for Infectious DiseasesR.M.Gorbacheva Memorial Institute of Oncology, Hematology and Transplantation, Pavlov First Saint Petersburg State Medical UniversityR.M.Gorbacheva Memorial Institute of Oncology, Hematology and Transplantation, Pavlov First Saint Petersburg State Medical UniversityFederal Research and Clinical Centre of Physical and Chemical Medicine of Federal Medical and Biological Agency of RussiaFederal Research and Clinical Centre of Physical and Chemical Medicine of Federal Medical and Biological Agency of RussiaFederal Research and Clinical Centre of Physical and Chemical Medicine of Federal Medical and Biological Agency of RussiaPediatric Research and Clinical Center for Infectious DiseasesFederal Research and Clinical Centre of Physical and Chemical Medicine of Federal Medical and Biological Agency of RussiaFederal Research and Clinical Centre of Physical and Chemical Medicine of Federal Medical and Biological Agency of RussiaFederal Research and Clinical Centre of Physical and Chemical Medicine of Federal Medical and Biological Agency of RussiaR.M.Gorbacheva Memorial Institute of Oncology, Hematology and Transplantation, Pavlov First Saint Petersburg State Medical UniversityR.M.Gorbacheva Memorial Institute of Oncology, Hematology and Transplantation, Pavlov First Saint Petersburg State Medical UniversityR.M.Gorbacheva Memorial Institute of Oncology, Hematology and Transplantation, Pavlov First Saint Petersburg State Medical UniversityR.M.Gorbacheva Memorial Institute of Oncology, Hematology and Transplantation, Pavlov First Saint Petersburg State Medical UniversityR.M.Gorbacheva Memorial Institute of Oncology, Hematology and Transplantation, Pavlov First Saint Petersburg State Medical UniversityR.M.Gorbacheva Memorial Institute of Oncology, Hematology and Transplantation, Pavlov First Saint Petersburg State Medical UniversityUniversitat Politècnica de CatalunyaUniversitat de GironaExplana Research LaboratoryR.M.Gorbacheva Memorial Institute of Oncology, Hematology and Transplantation, Pavlov First Saint Petersburg State Medical UniversityFederal Research and Clinical Centre of Physical and Chemical Medicine of Federal Medical and Biological Agency of RussiaFederal Research and Clinical Centre of Physical and Chemical Medicine of Federal Medical and Biological Agency of RussiaR.M.Gorbacheva Memorial Institute of Oncology, Hematology and Transplantation, Pavlov First Saint Petersburg State Medical UniversityAbstract Background Fecal microbiota transplantation (FMT) has been recently approved by FDA for the treatment of refractory recurrent clostridial colitis (rCDI). Success of FTM in treatment of rCDI led to a number of studies investigating the effectiveness of its application in the other gastrointestinal diseases. However, in the majority of studies the effects of FMT were evaluated on the patients with initially altered microbiota. The aim of our study was to estimate effects of FMT on the gut microbiota composition in healthy volunteers and to monitor its long-term outcomes. Results We have performed a combined analysis of three healthy volunteers before and after capsule FMT by evaluating their general condition, adverse clinical effects, changes of basic laboratory parameters, and several immune markers. Intestinal microbiota samples were evaluated by 16S rRNA gene and shotgun sequencing. The data analysis demonstrated profound shift towards the donor microbiota taxonomic composition in all volunteers. Following FMT, all the volunteers exhibited gut colonization with donor gut bacteria and persistence of this effect for almost ∼1 year of observation. Transient changes of immune parameters were consistent with suppression of T-cell cytotoxicity. FMT was well tolerated with mild gastrointestinal adverse events, however, one volunteer developed a systemic inflammatory response syndrome. Conclusions The FMT leads to significant long-term changes of the gut microbiota in healthy volunteers with the shift towards donor microbiota composition and represents a relatively safe procedure to the recipients without long-term adverse events.https://doi.org/10.1186/s12866-019-1689-yFecal microbiota transplantationHealthy volunteersMetagenomics16S rRNA gene sequencingShotgun sequencingMetagenome-assembled genome |